PAH may progress silently, even on

the days when you may feel fine1

PAH may progress silently, even on the days when you may feel fine1

Watch the Video
PAH progression doesn’t stop
Why should you?
Sign up to learn more
Your PAH may be progressing silently, even when your symptoms seem stable1
PAH can involve changes in the levels of three substances that occur naturally in your body. Over time, these changes can cause the arteries in your lungs to become thick and stiff. As this happens, the arteries of your lungs may tighten or narrow and scar, making it more difficult for blood to flow.2,3
When blood flow is restricted, your heart must work harder to pump blood through the arteries of your lungs. This can cause the muscles in your heart to thicken, which can make it more difficult for your heart to pump blood. As time goes on, the strain on your heart can progressively worsen.3
Watch this video
to learn more
The Quiz
Question 1
When my symptoms are stable, that means my pulmonary arterial hypertension (PAH) is not getting worse.
THE CORRECT ANSWER IS FALSE
Even when symptoms seem stable, your PAH may be progressing. The narrowing of the arteries in your lungs can make the heart work harder, increasing the strain on your heart.3
Next Question
Question 2
PAH involves changes in the levels of only two naturally occurring substances in the body.
THE CORRECT ANSWER IS FALSE
PAH can be driven by imbalances of three substances that occur naturally in your body. Over time, the changes in these substances can cause the arteries in your lungs to become thick and stiff.2
Next Question
Question 3
There are PAH treatments available that target three different pathways.
THE CORRECT ANSWER IS TRUE
There are medications available that work on each of the three key pathways.2 UPTRAVI® targets one of these pathways. Discussing a comprehensive treatment plan with your doctor that includes UPTRAVI® may help you delay the progression of your PAH.4
PAH can progress rapidly in patients with connective tissue disease such as scleroderma5
If you have PAH associated with scleroderma, you may want to learn how it might affect you.
Find out if there is an additional treatment angle you could try to help delay PAH progression3
IMPORTANT SAFETY INFORMATION
EXPAND +
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
  • Do not take UPTRAVI® if you are allergic to selexipag or any of the ingredients in UPTRAVI®
  • Before you take UPTRAVI®, tell your healthcare provider about all your medical conditions, including if you:
    • Have liver problems
    • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
    • Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby
    • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
    • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

What are the possible side effects of UPTRAVI®?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain, redness or swelling at the injection site with UPTRAVI® for injection
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI® and all other medicines away from children.

What other medicines might interact with UPTRAVI®?

UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI®?
UPTRAVI® Tablets
  • Take UPTRAVI® exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI® twice a day. Taking UPTRAVI® with food may help you tolerate UPTRAVI® better
  • Swallow UPTRAVI® tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI®
  • UPTRAVI® is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
UPTRAVI® given by intravenous (IV) injection
  • Your healthcare provider will give you UPTRAVI® into your vein through an intravenous (IV) line
  • Your healthcare provider will decide how much UPTRAVI® for injection you will receive each day based on your current dose of UPTRAVI® tablets
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

cp-113991v5

+
IMPORTANT SAFETY INFORMATION
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
+
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension

IMPORTANT SAFETY INFORMATION
  • Do not take UPTRAVI® if you take gemfibrozil because this medicine may affect how UPTRAVI® works and cause side effects
  • Do not take UPTRAVI® if you are allergic to selexipag or any of the ingredients in UPTRAVI®
  • Before you take UPTRAVI®, tell your healthcare provider about all your medical conditions, including if you:
    • Have liver problems
    • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
    • Are pregnant or plan to become pregnant. It is not known if UPTRAVI® will harm your unborn baby
    • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI® passes into your breast milk. You and your doctor should decide if you will take UPTRAVI® or breastfeed. You should not do both
    • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

What are the possible side effects of UPTRAVI®?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain, redness or swelling at the injection site with UPTRAVI® for injection
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI®. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI® and all other medicines away from children.

What other medicines might interact with UPTRAVI®?

UPTRAVI® and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor.

How should I take UPTRAVI®?
UPTRAVI® Tablets
  • Take UPTRAVI® exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI® twice a day. Taking UPTRAVI® with food may help you tolerate UPTRAVI® better
  • Swallow UPTRAVI® tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI®
  • UPTRAVI® is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
UPTRAVI® given by intravenous (IV) injection
  • Your healthcare provider will give you UPTRAVI® into your vein through an intravenous (IV) line
  • Your healthcare provider will decide how much UPTRAVI® for injection you will receive each day based on your current dose of UPTRAVI® tablets
What is UPTRAVI®?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI® is safe and effective in children.

cp-113991v5

References: 1. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143-155. 2. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189-2208. 3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294. 4. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 5. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii25-31.